NCT06831539

Brief Summary

The main objective is to evaluate the impact of intestinal preparation on the composition, diversity and metabolome of the intestinal microbiota.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for phase_1 cancer

Timeline
6mo left

Started Dec 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Dec 2024Dec 2026

Study Start

First participant enrolled

December 5, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 13, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 18, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2026

Last Updated

February 19, 2025

Status Verified

February 1, 2025

Enrollment Period

1.7 years

First QC Date

February 13, 2025

Last Update Submit

February 17, 2025

Conditions

Keywords

PegLyteMicrobiome

Outcome Measures

Primary Outcomes (1)

  • To evaluate the impact of bowel preparation on the gut microbiota at 1 week after bowel preparation.

    Study of the gut microbiota composition at 1 week after bowel preparation.

    At week 1

Secondary Outcomes (1)

  • Gut microbiome composition, diversity, and gut metabolome profile at 1 month and 3 months after bowel preparation

    At 1 month and 3 months

Study Arms (1)

Healthy volunteer participant cohort

EXPERIMENTAL

For healthy volunteer participants, PEG bowel preparation will be administered and participants will collect stool samples before and after PEG at specified timepoints.

Drug: PEGLyte bowel preparation

Interventions

Volunteers will be administered 4L of PEG bowel preparation. The following instructions will be provided with the prescription: 1. Fill the supplied container containing the bowel cleanse powder with lukewarm water (to facilitate dissolution) to the 4-liter fill line. The solution is clear and colourless when reconstituted to a final volume of 4 liters. 2. After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. The solution is more palatable if chilled prior to drinking. When reconstituted use within 48 hours. 3. Attempt to drink a maximum of 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters has been consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. 4. The first bowel movements should occur approximately one hour after the start of bowel cleanse administration. Continue drinking until the watery stool is clear and free of solid matter.

Also known as: PEG
Healthy volunteer participant cohort

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteer participant cohort:
  • \> 18 years of age
  • The participant has provided documented informed consent for the participation and to complete PEG bowel preparation and return collected stool samples.

You may not qualify if:

  • An ileus
  • Significant gastric retention
  • Suspected or established mechanical bowel obstruction
  • Inflammatory or infectious gastrointestinal condition
  • Neurologic or cognitive impairment that prevents safe swallowing
  • Recent history (\<1 year) of cancer that still requires ongoing treatment
  • Recent use of antibiotics 1 month prior to participation in the trial
  • History of cardiac disease
  • History of active renal dysfunction
  • Presence of any absolute contraindication to PEG bowel preparation according to manufacturer labeling

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, H2X 3E4, Canada

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Arielle Elkrief, MD

    Centre hospitalier de l'Université de Montréal (CHUM)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: This is a single-arm study evaluating the impact of PEG bowel preparation on the gut microbiome in volunteer participants.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 13, 2025

First Posted

February 18, 2025

Study Start

December 5, 2024

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 5, 2026

Last Updated

February 19, 2025

Record last verified: 2025-02

Locations